Tisagenlecleucel - Novartis/University of Pennsylvania
At a glance
- Drug Originator Lentigen Corporation; University of Pennsylvania
- Drug Licenced by Novartis
- Drug Class Antineoplastics; CAR-T cell therapies; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
- USA Patent Applicants NOVARTIS PHARMACEUTICALS CORPORATION
- USA Patents 5
- BLAs 1
- International Patents 77
Disclaimer